



PRIOR AUTHORIZATION POLICY

- POLICY:** Growth Disorders – Sogroya Prior Authorization Policy
- Sogroya® (somapacitan-beco subcutaneous injection – Novo Nordisk)

REVIEW DATE: 05/31/2023; selected revision 11/01/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Sogroya, a long-acting human growth hormone (hGH) analog, is indicated for the treatment of pediatric patients ≥ 2.5 years of age who have growth failure due to inadequate secretion of growth hormone (GH).¹ Sogroya is also indicated for the replacement of endogenous GH in adults with GH deficiency (GHD).

Disease Overview

GHD in Children and Adolescents

Sogroya is a hGH analog.¹ In children with GHD, somatropin is effective for increasing final adult height.² Somatropin therapy is recommended to normalize adult height and avoid extreme shortness in children and adolescents with GHD.² In addition to congenital causes, hypopituitarism may also be caused by radiation therapy; somatropin may be used to improve final height of children who have undergone radiation.^{3,4}

GHD in Adults or Transition Adolescents

Somatropin is indicated for the replacement of endogenous GH in adults with GH, which may present in adults or children as GHD.¹¹ Patients with other anterior pituitary hormone deficiencies are likely to have GHD. In adults, the diagnosis of GHD usually is made in patients with signs and symptoms of hypothalamic-pituitary

disease (endocrine, structural, and/or genetic causes); those who have received cranial irradiation or tumor treatment; or those with traumatic brain injury or subarachnoid hemorrhage.^{11,12} Onset may be in adulthood or childhood. In childhood, the goal of somatropin therapy is primarily for statural growth. When final adult height is attained, somatropin therapy is no longer required for statural growth. Transition is used to describe the period in adolescence after growth is completed and the need for continued replacement into adulthood is assessed. Confirmatory GH stimulation testing may not be required in patients, such as those with congenital/genetic GHD or multiple pituitary hormone deficiencies. When persistent GHD is documented after completion of adult height, somatropin therapy should be continued to attain full skeletal and muscle maturation during the transition period from childhood to adulthood.¹¹ In adults with GHD, somatropin replacement therapy improves abnormalities in substrate metabolism, body composition, and physical and psychosocial function.^{11,12} GH is not approved by the FDA for the treatment of other conditions in adults who may have a low GH response to GH provocative testing (such as obesity, aging, or depression) or to improve athletic performance.^{13,14}

Guidelines

Current guidelines do not specifically address Sogroya. Neither the Pediatric Endocrine Society guidelines for children and adolescents with GH deficiency² (2016) nor the GH Research Society guidelines on children with short stature¹⁵ (2019) recommend a specific GH product for GHD. Both publications note that newer long-acting GH preparations may reduce the frequency of injections. The American Association of Clinical Endocrinologists and the American College of Endocrinology guidelines for management of GHD in adults and patients transitioning from pediatric to adult care¹⁶ (2019) also do not prefer one GH agent over another. These guidelines state that when the clinician is suspicious of adult GHD, establishing a diagnosis is essential before replacement with GH. Adult GHD is associated with numerous adverse metabolic abnormalities (abdominal obesity, reduced lean body mass, increased peripheral insulin resistance, impaired cardiac performance) which may contribute to increased cardiovascular morbidity and mortality.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Sogroya. All reviews will be directed to a clinician (i.e., pharmacist) for verification of criteria. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Sogroya as well as monitoring required for adverse events and long-term efficacy, initial approval requires the patient to be evaluated by a physician who specializes in the condition being treated. Human growth hormone is FDA-approved for treatment of a limited number of conditions. The FDA has not approved the use of human growth hormone as therapy for anti-aging, longevity, cosmetic or performance enhancement. Federal law prohibits the dispensing of human growth hormone for non-approved purposes. A pharmacy's failure to comply with that law could result in significant criminal penalties to the pharmacy and its employees. Accordingly, a pharmacy may decline to dispense prescriptions for human growth hormone when written by a physician or other authorized prescribers who they believe may be involved in or affiliated with

the fields of anti-aging, longevity, rejuvenation, cosmetic, performance enhancement, or sports medicine.

Documentation: Documentation is required for use of Sogroya as noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, prescription claims records, prescription receipts, and/or other information. For patient cases in which documentation is required, if this documentation has been previously received upon a prior coverage review, the documentation requirement is considered to be met.

- **Sogroya® (somapacitan-beco subcutaneous injection (Novo Nordisk)**

is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indication

1. Growth Hormone Deficiency in a Child or Adolescent (≥ 2.5 years of age).

Approve for 1 year if the patient meets ONE the following (A or B):

A) Initial Therapy with any Growth Hormone Agent. Approve if the patient meets ONE of the following (i, ii, iii, iv, or v):

i. Patient meets BOTH of the following (a and b):

a) Patient meets ONE of the following (1 or 2):

(1) Patient has had two growth hormone stimulation tests performed with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon AND the peak growth hormone response to both tests are < 10 ng/mL; OR

(2) Patient meets BOTH of the following criteria (i and ii):

(i) Patient has had at least one growth hormone stimulation test performed with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon AND the peak growth hormone response to at least one test is < 10 ng/mL; AND

(ii) Patient has at least one risk factor for growth hormone deficiency; AND

Note: Examples of at least one risk factor for growth hormone deficiency includes: the height for age curve has deviated downward across two major height percentiles (e.g., from above the 25th percentile to below the 10th percentile); the child's growth rate is less than the expected normal growth rate based on age and gender; low insulin-like growth factor (IGF)-1 and/or IGFBP-3 levels; the child has a very low peak growth hormone level on provocative testing as defined by the prescribing physician; the child's growth velocity is less than the 10th percentile for age and gender (height velocity percentile is NOT the same as height-for-age percentile); the patient is status post craniopharyngioma

- resection; the patient has optic nerve hypoplasia; the patient has a growth hormone gene deletion; AND
- b)** Patient has been evaluated by an endocrinologist.
- ii.** Patient has undergone brain radiation or tumor resection AND meets BOTH of the following (a and b):
- a)** Patient meets at least ONE of the following (1 or 2):
- (1)** Patient meets BOTH of the following (i and ii):
- (i)** Patient has had at least one growth hormone stimulation test performed with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon; AND
- (ii)** The peak growth hormone response to at least one test is < 10 ng/mL; OR
- (2)** Patient has a deficiency in at least one other pituitary hormone (i.e., adrenocorticotrophic hormone, thyroid-stimulating hormone, gonadotropin [luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency], or prolactin); AND
- b)** Patient has been evaluated by an endocrinologist.
- iii.** Patient has congenital hypopituitarism AND meets BOTH of the following (a and b):
- a)** Patient meets at least ONE of the following (1, 2, or 3):
- (1)** Patient meets BOTH of the following (i and ii):
- (i)** Patient has had at least one growth hormone stimulation test performed with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon; AND
- (ii)** The peak growth hormone response to at least one test is < 10 ng/mL; OR
- (2)** Patient has a deficiency in at least one other pituitary hormone (i.e., adrenocorticotrophic hormone, thyroid-stimulating hormone, gonadotropin [luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency], or prolactin); OR
- (3)** Patient has the imaging triad of ectopic posterior pituitary and pituitary hypoplasia with abnormal pituitary stalk; AND
- b)** Patient has been evaluated by an endocrinologist.
- iv.** Patient has multiple pituitary hormone deficiencies and meets BOTH of the following (a and b):
- Note: Growth hormone deficiency may occur in combination with other pituitary hormone deficiencies and is referred to as hypopituitarism, panhypopituitarism, or multiple pituitary hormone deficiency.
- a)** Patient meets at least ONE of the following (1 or 2):
- (1)** Patient has three or more of the following pituitary hormone deficiencies: somatotropin (growth hormone), adrenocorticotrophic hormone, thyroid-stimulating hormone, gonadotropin (luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency), and prolactin; OR
- (2)** Patient meets BOTH of the following (i and ii)

- (i) Patient had one growth hormone stimulation test with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon; AND
- (ii) The peak growth hormone response to at least one test is < 10 ng/mL; AND
- b) Patient has been evaluated by an endocrinologist.
- v. Patient has had a hypophysectomy (surgical removal of pituitary gland).
- B) Patient is Currently Receiving Sogroya or is switching to Sogroya from another Growth Hormone Agent (Patient has been established on either therapy for \geq 10 months).** Approve if the patient meets one of the following (i, ii, or iii):
 - i. Patient is < 12 years of age: Patient's height has increased by \geq 2 cm/year in the most recent year; OR
 - ii. Patient is \geq 12 years of age and < 18 years of age: Patient meets both of the following (a and b):
 - a) Patient's height has increased by \geq 2 cm/year in the most recent year; AND
 - b) Patient's epiphyses are open.
 - iii. Patient is \geq 18 years of age. Patient meets ALL of the following (a, b, and c):
 - a) Patient's height has increased by \geq 2 cm/year in the most recent year; AND
 - b) Patient's epiphyses are open; AND
 - c) Mid-parental height has not been attained.
 Note: Mid-parental height is the father's height plus the mother's height divided by 2, plus 2.5 inches if male or minus 2.5 inches if female.
 Note: Adolescents and young adults with childhood onset growth hormone deficiency who have completed linear growth may continue receiving Sogroya therapy as a transition adolescent or as an adult. See criteria for Growth Hormone Deficiency in an adult or transition adolescent.

2. Growth Hormone Deficiency in an Adult or Transition Adolescent. Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

- A)** The endocrinologist must certify that growth hormone therapy is not being prescribed for anti-aging therapy or to enhance athletic ability or for body building; AND
- B)** Patient must have a diagnosis of growth hormone deficiency that is ONE of the following (i or ii): **[documentation required for all elements]**
 - i. Childhood onset; OR
 - ii. Adult onset that results from one of the following: growth hormone deficiency alone or multiple hormone deficiencies (hypopituitarism) resulting from pituitary disease, hypothalamic disease, pituitary surgery, cranial radiation therapy, tumor treatment, traumatic brain injury, or subarachnoid hemorrhage; AND
- C)** Patient meets at least ONE of the following (i, ii, or iii):
 - i. Patient (adult or transition adolescent) has known perinatal insults OR congenital or genetic defects; **[documentation required]** OR
 - ii. Patient meets ALL of the following (a, b, and c):

- a) Patient (adult onset or transition adolescent) has three or more of the following pituitary hormone deficiencies: Adrenocorticotrophic hormone , thyroid-stimulation hormone, gonadotropin deficiency (luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency), and prolactin **[documentation required]**; AND
 - b) The age and gender adjusted serum insulin-like growth factor-1 is below the lower limit of the normal reference range for the reporting laboratory **[documentation required]**; AND
 - c) Other causes of low serum insulin-like growth factor-1 have been excluded (e.g., malnutrition, prolonged fasting, poorly controlled diabetes mellitus, hypothyroidism, hepatic insufficiency, oral estrogen therapy); OR
- iii. Patient meets at least ONE of the following (a or b):
- a) Adult. Patient has had a negative response to at least ONE of the following standard growth hormone stimulation tests (1, 2, 3, 4, 5, or 6) **[documentation required for all elements]**:
Note: If the patient has had a previous trial of an arginine test with a peak response of ≤ 0.4 mcg/L, this would meet the criteria for a negative response to a growth hormone stimulation test.
 - (1) Insulin tolerance test (obtaining at least 3 growth hormone levels in at least a 60 minute timeframe [not including a level at timeframe zero], with adequate hypoglycemia being achieved) with peak response ≤ 5.0 mcg/L; OR
 - (2) Glucagon stimulation test (obtaining at least 3 growth hormone levels in at least 180 minute timeframe [not including a level at timeframe zero]) with peak response ≤ 3.0 mcg/L AND the patient's body mass index (BMI) is < 25 kg/m²; OR
 - (3) Glucagon stimulation test (obtaining at least 3 growth hormone levels in at least 180 minute timeframe [not including a level at timeframe zero]) with a peak response ≤ 3.0 mcg/L AND the patient's BMI is ≥ 25 kg/m² and ≤ 30 kg/m² with, according to the prescriber, a high pretest probability of growth hormone deficiency; OR
 - (4) Glucagon stimulation test (obtaining at least 3 growth hormone levels in at least 180 minute timeframe [not including a level at timeframe zero]) with a peak response ≤ 1.0 mcg/L AND the patient's BMI is ≥ 25 kg/m² and ≤ 30 kg/m² with, according to the prescriber, a low pretest probability of growth hormone deficiency; OR
 - (5) Glucagon stimulation test (obtaining at least 3 growth hormone levels in at least 180 minute timeframe [not including a level at timeframe zero]) with peak response ≤ 1.0 mcg/L AND the patient's BMI is > 30 kg/m²; OR
 - (6) Macrilen (macimorelin oral solution) test (obtaining at least 4 growth hormone levels in at least a 90 minute timeframe [not including a level at timeframe zero]) with peak responses < 2.8 ng/mL (2.8 mcg/L) AND the patient's BMI is ≤ 40 kg/m².

Note: The following formula can be used to calculate BMI: BMI equals body weight in kg divided by height meters squared (m^2) [i.e., $BMI = kg/m^2$]; OR

- b) Transition adolescent.** Patient meets BOTH of the following (1 and 2):
[documentation required for all elements]:

Note: The transition period is the time from late puberty to establishment of adult muscle and bone composition, and encompasses attainment of adult height.

Note: If the patient has had a trial of a Macrilen test with a peak response of < 2.8 ng/mL (mcg/L), this would meet the criteria for a negative response to a growth hormone stimulation test.

(1) Patient has been off growth hormone therapy for at least 1 month before retesting with a growth hormone stimulation test; AND

(2) Patient meets at least ONE of the following responses to growth hormone stimulation testing (i, ii, iii, iv, v or vi):

(i) Insulin tolerance test (obtaining at least 3 growth hormone levels in at least a 60 minute timeframe [not including a level at timeframe zero], with adequate hypoglycemia being achieved) with peak response ≤ 5.0 mcg/L; OR

(ii) Glucagon stimulation test (obtaining at least 3 growth hormone levels in at least 180 minute timeframe [not including a level at timeframe zero]) with peak response ≤ 3.0 mcg/L AND the patient's body mass index (BMI) is < 25 kg/m^2 ; OR

(iii) Glucagon stimulation test (obtaining at least 3 growth hormone levels in at least 180 minute timeframe [not including a level at timeframe zero]) with a peak response of ≤ 3.0 mcg/L AND the patient's BMI is ≥ 25 kg/m^2 and ≤ 30 kg/m^2 with, according to the prescriber, a high pretest probability of growth hormone deficiency; OR

(iv) Glucagon stimulation test (obtaining at least 3 growth hormone levels in at least 180 minute timeframe [not including a level at timeframe zero]) with a peak response ≤ 1.0 mcg/L AND the patient's BMI is ≥ 25 kg/m^2 and ≤ 30 kg/m^2 with, according to the prescriber, a low pretest probability of growth hormone deficiency; OR

(v) Glucagon stimulation test (obtaining at least 3 growth hormone levels in at least 180 minute timeframe [not including a level at timeframe zero]) with peak response ≤ 1.0 mcg/L AND the patient's BMI is > 30 kg/m^2 ; OR

(vi) If both the insulin tolerance test AND glucagon stimulation test are contraindicated, the arginine test can be used (obtaining at least 3 growth hormone levels in at least 120 minute timeframe [not including a level at timeframe zero]) with a peak response ≤ 0.4 mcg/L; AND

D) Patient has been evaluated by an endocrinologist.

CONDITIONS NOT COVERED

- **Sogroya® (somapacitan-beco subcutaneous injection (Novo Nordisk)**

is(are) considered experimental, investigational or unproven for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

Note: For some of the following indications, authorization for coverage is not recommended because this indication is excluded from coverage in a typical pharmacy benefit.

- 1. Acute Critical Illness Due to Complications Following Surgery, Multiple Accidental Trauma, or with Acute Respiratory Failure.**¹ Sogroya is contraindicated in acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or those with acute respiratory failure because of the risk of increased mortality.
- 2. Aging (i.e., Anti-Aging), to Improve Functional Status in an Elderly Patient, and Somatopause.**^{13,14,17,18} Somatropin is not FDA-approved for anti-aging therapy, to improve functional status in elderly patients, or to treat somatopause. Federal law prohibits the distribution or dispensing of somatropin for non-FDA approved uses. There are no long-term studies assessing somatropin efficacy and safety for anti-aging therapy. Short-term therapy with somatropin may improve some measures of body composition, including increased muscle mass, reduced total body fat, improved skin elasticity, and reduced rate of bone demineralization, but somatotropin does not have positive effects on strength, functional capacity, or metabolism. Somatropin is associated with considerable adverse effects in non-growth hormone deficient adults (e.g., carpal tunnel syndrome, soft tissue edema, arthralgias, glucose intolerance, increased serum lipids). Another concern is the possible increased risk of cancer with long-term use of somatropin and the potentiating effects of IGFs on cancer. Somatropin is not indicated for the age-related decrease in growth hormone/IGF-1 status.¹²
- 3. Athletic Ability Enhancement.**⁵ Somatropin is not FDA-approved for athletic performance enhancement or for body building in nonathletes. Federal law prohibits the distribution or dispensing of somatropin for non-FDA approved uses. Short-term administration of somatropin to increase strength and endurance in athletes is no more effective than training alone and somatropin should not be administered to athletes or other persons for the purpose of enhancing athletic ability or improving personal appearance (i.e., to appear leaner and more muscular). Somatropin has been used in supraphysiologic doses alone or in combination with other performance enhancing drugs (PEDs) in users who are not athletes.³⁴ Use of PEDs has been linked to an increased risk of death and many adverse effects including cardiovascular, psychiatric, metabolic, endocrine, neurologic, infectious, hepatic, renal, and musculoskeletal disorders.
- 4. Central Precocious Puberty.** Children with precocious puberty are often treated with gonadotropin releasing hormone (GnRH) agonists (Lupron® [leuprolide

acetate injection]) to suppress pituitary gonadal activity, to slow the advancement of bone age (prevent premature fusion of the epiphyseal growth plates), and to improve adult height. In some patients GnRH agonist therapy may result in marked deceleration of bone growth and may result in adult height that is less than the mid-parental height. Somatropin has been used in girls when growth velocity decreases or if it appears that the targeted adult height will not be attained.⁶ There are no large well-controlled trials on the efficacy and safety of adding somatropin to GnRH agonist therapy in these children or the effect on final height.^{6,7}

- 5. Chronic Fatigue Syndrome.** There is no evidence of GHD in chronic fatigue syndrome.¹⁹
- 6. Congenital Adrenal Hyperplasia (CAH).**^{8,9} The Endocrine Society clinical practice guidelines on CAH due to steroid 21-hydroxylase deficiency recommend against the use of experimental treatment approaches outside of formally approved clinical trials.⁹ Children with predicted adult height standard deviation ≤ -2.25 may be considered for growth-promoting treatments in appropriately controlled trials.
- 7. Constitutional Delay of Growth and Puberty.** These children have delayed skeletal maturation and pubertal development. Administering somatropin does not increase adult height (which is usually normal).¹⁰ Short-term androgen therapy accelerates growth and the rate of pubertal advancement in boys.
- 8. Fibromyalgia.** In one placebo-controlled study, 120 non-GHD adult women with severe fibromyalgia and low levels of IGF-1 were randomized to somatropin 0.006 mg/kg/day for 12 months (dose was adjusted) or placebo for 6 months.²⁰ Patients receiving placebo initially were switched to somatropin from Months 6 to 12 (open label). Standard therapy for fibromyalgia was continued. After 6 months, there were no differences between somatropin and placebo in the percentage of patients with fewer than 11 positive tender points, mean number of tender points, intensity of pain in every point evaluated, and other measures. After 12 months of somatropin therapy, 53% of patients had less than 11 positive tender points compared with 33% of patients who received placebo and then somatropin for 6 months ($P < 0.05$). At 18 months follow-up evaluation when somatropin was discontinued, impairment in pain perception worsened in both groups but to a lesser extent in the patients on somatropin for 12 months. Further controlled trials are needed with a longer duration,²¹ with different doses, and using the 2010 American College of Rheumatology criteria for fibromyalgia. Some patients with fibromyalgia may have adult GHD.
- 9. Infertility.**^{22,23} Clinical trials indicate that somatropin is not useful as an adjunct during in vitro fertilization, for induction of ovulation in polycystic ovary syndrome, or for assisted reproductive technology. The authors of a recent meta-analysis concluded there is no evidence of an increased chance of a live birth with use of somatropin.

- 10. Obesity.**^{24,25} Somatropin is not indicated for the treatment of obesity. Low growth hormone levels are a consequence of central obesity and not a cause. Obesity is associated with decreased basal and pulsatile release of growth hormone and decreased stimulated growth hormone release. Somatropin therapy does not have significant beneficial effects on obesity in persons without GHD and does not produce significant overall weight loss. Supraphysiologic doses of somatropin have been used to treat obesity. Effects of long-term therapy with somatropin are unknown.
- 11. Osteoporosis.**^{26,27} Guidelines for treatment or prevention of osteoporosis do not include recommendations for use of somatropin. In one double-blind trial, 80 postmenopausal women with osteoporosis (56% of patients [n = 45/80] had a history of fractures) were randomized to somatropin 0.33 mg/day or 0.83 mg/day or to placebo for three years.²⁶ The double-blind phase was 18 months and patients on somatropin continued drug for another 18 months and patients on placebo stopped at 18 months. Patients were compared with an age-matched random population sample of women (n = 120). All patients received calcium 750 mg, vitamin D 400 units, and hormone replacement therapy. All women were followed for 10 years total. Bone mineral density increased in the patients receiving somatropin at years 4 and 5, and after 10 years, had decreased to similar levels as before treatment. At 10 years, 28% of women (n = 22/80) had had fractures. In the control group, fractures increased from 8% of patients at baseline to 32% of patients after 10 years. At 10 years, 41% of patients (n = 33/80) had stopped hormone replacement therapy; 23% had started bisphosphonates due to fractures, and 3% had received Forteo® (teriparatide injection). Larger studies are needed to determine the effects of somatropin therapy on bone mineral density and fractures in non-growth hormone deficient persons.

REFERENCES

1. Sogroya® subcutaneous injection [prescribing information]. Plainsboro, NJ: Novo Nordisk; April 2023.
2. Grimberg A, DiVall SA, Polychronakos C, et al; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. *Horm Res Paediatr*. 2016;86(6):361-397.
3. Melmed S. Idiopathic adult growth hormone deficiency. *J Clin Endocrinol Metab*. 2013;98:2187-2197.
4. Isfan F, Kanold J, Merlin E, et al. Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA). *Bone Marrow Transplant*. 2012;47:684-693.
5. Clemmons DR, Molitch M, Hoffman AR, et al. Growth hormone should be used only for approved indications. *J Clin Endocrinol Metab*. 2014;99:409-411.
6. Carel JC, Eugster EA, Rogol A, et al on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009;123:e752-762.
7. Carel JC, Leger J. Precocious puberty. *N Engl J Med*. 2008;358:2366-2377.
8. Lin-Su K, Harbison MD, Lekarev O, et al. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. *J Clin Endocrinol Metab*. 2011;96:1710-1717.

9. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2018;103(11):4043-4088.
10. De Luca F, Argente J, Cavallo L, et al; International Workshop on Management of Puberty for Optimum Auxological Results. Management of puberty in constitutional delay of growth and puberty. *Pediatr Endocrinol Metab.* 2001;14 Suppl 2:953-957.
11. Molitch ME, Clemmons DR, Malozowski S, et al; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96:1587-1609.
12. Ho KK; 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. *Eur J Endocrinol.* 2007;157:695-700.
13. Melmed S. Idiopathic adult growth hormone deficiency. *J Clin Endocrinol Metab.* 2013;98:2187-2197.
14. Clemmons DR, Molitch M, Hoffman AR, et al. Growth hormone should be used only for approved indications. *J Clin Endocrinol Metab.* 2014;99:409-411.
15. Collett-Solberg PF, Ambler G, Backelijaw PF, et al. Diagnosis, genetics, and therapy of short stature in children: A growth hormone research society international perspective. *Horm Res Paediatr.* 2019;92(1):1-14.
16. Yuen K, Biller B, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. *Endocr Pract.* 2019;25(11):1191-1232.
17. Vance ML. Can growth hormone prevent aging? *N Engl J Med.* 2003;348:779-780.
18. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. *Ann Intern Med.* 2007;146:104-115.
19. Cleare AJ, Sookdeo SS, Jones J, et al. Integrity of the growth hormone/insulin-like growth factor system is maintained in patients with chronic fatigue syndrome. *J Clin Endocrinol Metab.* 2000;85:1433-1439.
20. Cuatrecasas G, Alegre C, Fernandez-Solà J, et al. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. *Pain.* 2012;153:1382-1389.
21. Geenen R, Jacobs JW, Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. *Rheum Dis Clin North Am.* 2002;28:389-404.
22. Hart RJ, Rombauts L, Norman RJ. Growth hormone in IVF cycles: any hope? *Curr Opin Obstet Gynecol.* 2017;29(3):119-125.
23. Homburg R, Singh A, Bhide P, et al. The re-growth of growth hormone in fertility treatment: a critical review. *Hum Fertil (Camb).* 2012;15:190-193.
24. Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. *Obes Res.* 2003;11:170-175.
25. Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a meta-analysis. *J Clin Endocrinol Metab.* 2009;94:130-137.
26. Krantz E, Timpou P, Landin-Wilhelmsen K. Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: A 10-Year follow-up study. *J Clin Endocrinol Metab.* 2015;100:3251-3259.
27. Gillberg P, Mallmin H, Petren-Mallmin M, et al. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. *J Clin Endocrinol Metab.* 2002;87:4900-4906.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	05/31/2023
Selected Revision	Growth Hormone Deficiency in a Child or Adolescent (≥ 2.5 years of age): Criterion that specified the result of a growth hormone stimulation test to be < 10 ng/mL was added. Criterion that the	11/01/2023

	stimulation test show an inadequate response as defined by a peak response below the normal reference range as determined by the testing laboratory was removed.	
--	--	--

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna